3 Beaten-Down Biotech Stocks That Could Double

Officers and directors of the nation's smallest and youngest biotech companies can look up their stock quotes once again.
Stocks in the sector were in such rapid freefall a few months ago that a glance at the stock price chart became too painful to bear.
How painful was the sell-off?

I counted 30 biotech stocks that shed at least 40% of their value in the past three months, with half of them plunging by more than 50%.  (more)


Please share this article